Ari Alexandrou

Mechanism of hERG K⁺channel blockade by the fluoroquinolone antibiotic moxifloxacin

Ari Alexandrou, Rona S. Duncan, Jules C. Hancox et al. · British Journal of Pharmacology · 2006 · 114 citations · Full text

Natural Sciences, Medicinal Chemistry, Pharmacology +17

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study

Joyce O’Shaughnessy, Susana Sousa, Josefina Cruz et al. · European Journal of Cancer · 2021 · 74 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study

Joseph Gligorov, Xavier Pivot, Beyhan Ataseven et al. · The Breast · 2022 · 11 citations · Full text

Medicine, Oncology, Pharmacology +17

165MO Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study

Joyce O’Shaughnessy, Susana Sousa, Juan Jesús Cruz et al. · Annals of Oncology · 2020 · 10 citations · Full text

Medicine, Oncology, Pharmacology +14